Clinical features of psoriatic arthritis

American Journal of Managed Care

Volumn 8, Issue 6 SUPPL., 2002, Pages

  Krueger, Gerald G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; BIOLOGICAL RESPONSE MODIFIER; CYCLOSPORIN; CYTOKINE; ETANERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTHROPATHY; BONE REMODELING; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENTHESITIS; ENTHESOPATHY; GENETICS; HUMAN; IMMUNOLOGY; INTERPHALANGEAL JOINT; LONG TERM CARE; META ANALYSIS; MOLECULAR BIOLOGY; MONARTHRITIS; POLYARTHRITIS; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN INFLAMMATION; SPINE DISEASE; SYNOVITIS;

ARTHRITIS, PSORIATIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; PREVALENCE; UNITED STATES;

EID: 0036344554     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
2. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
3. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
4. Infliximab (chimeric anti-tumor necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
5. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
6. Psoriatic arthritis (PA): A clinical, immunological, and radiological study of 180 patients
7. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease
8. Psoriatic arthritis (PsA) - An analysis of 220 patients
9. Validating the SF-36 health questionnaire in patients with psoriatic arthritis
10. Longitudinal study of clinical and radiological progression in psoriatic arthritis
11. Psoriatic arthritis: A quantitative overview of therapeutic options
12. Psoriatic arthritis fact sheet
13. Psoriatic arthritis
14. Baseline relationships between psoriasis and psoriatic arthritis: Analysis of 221 patients with active psoriatic arthritis
15. Rheumatism and psoriasis: A re-evaluation
16. Treatment of refractory psoriatic arthritis
17. Methotrexate use in psoriasis and psoriatic arthritis
18. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis
19. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate, and placebo in patients with psoriatic arthritis
20. Sulfasalazine in psoriatic arthritis: A double-blind placebo-controlled study
21. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis
22. Methotrexate therapy in psoriatic arthritis
23. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis
24. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
25. Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis
26. Psoriatic arthritis: Evolving concepts
27. New research shows one million U.S. Adults suffer from psoriatic arthritis. Others may be at risk but not know it
28. Selective T cell targeting in psoriasis: A novel approach to improve clinical outcomes
29. Incidence of psoriatic arthritis in Finland
30. Psoriasis
31. Acute guttate psoriasis and streptococcal infection
32. Psoriatic arthritis
33. HLA antigens in psoriatic arthritis
34. Psoriatic arthritis. A unified concept twenty years on
35. Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model
36. Psoriatic arthritis
37. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis
38. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis
39. The clinical features of rheumatoid arthritis
40. Psoriatic arthritis
41. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
42. New treatments for psoriasis
43. The immunologic and genetic basis of psoriasis
44. Mechanisms of disease: Inflammatory skin diseases, T cells, and immune surveillance
45. Pathogenesis of psoriatic arthritis
46. Macrophage-derived cytokine and nuclear factor kb p65 expression in synovial membrane and skin of patients with psoriatic arthritis
47. Patterns of cytokine production in psoriatic synovium
48. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid
49. Antideoxyribonuclease B titers in psoriasis
50. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies and Behçet's syndrome
51. The pathogenesis of psoriatic arthritis
52. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondyloarthropathy
53. MR imaging in seronegative spondylarthritis
54. Classification of inflammatory arthritis by enthesitis
55. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Systematic study of specimens from patients and control subjects